Benoit You, MD, PhD, discusses the findings of the phase 2 TROPHIMMUN study which treated chemotherapy-resistant gestational trophoblastic tumors with avelumab.
Benoit You, MD, PhD, academic staff physician in the Medical Oncology Department of Lyon University Hospital, discusses the findings of the phase 2 TROPHIMMUN study which treated chemotherapy-resistant gestational trophoblastic tumors with avelumab (Bavencio).
Investigators enrolled a total of 15 patients and out of those, 8 experienced hCG normalization, says You. They found that patients could stop avelumab and none presented with any relapse with 25 months of follow-up, and within 29 months, patients had successful treatment with avelumab. One patient who was successfully treated with avelumab was able to develop a normal pregnancy 1 year after the discontinuation of avelumab and normalization of hCG; this was the first report of a normal pregnancy after successful treatment with immunotherapy, says You. The 7 remaining patients who were resistant to avelumab were successfully treated with chemotherapy with or without surgery, concludes You.